Products for Research Use Only

(E/Z) -Rilzabrutinib

CAT: 0804-HY-151232Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-151232Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Rilzabrutinib (PRN1008) is an orally active Bruton's tyrosine kinase (BTK) inhibitor with anti-inflammatory and immunomodulatory activities. Rilzabrutinib can be used in the research of various inflammatory and immune-related diseases such as acute respiratory distress syndrome and sepsis[1].
CAS Number
1575591-66-0
Product Name Alternative
(E/Z) -PRN1008
UNSPSC
12352005
Hazard Statement
H315-H319
Target
Btk
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
NC1=C2C(C3=C(C=C(OC4=CC=CC=C4)C=C3)F)=NN([C@H]5CN(CCC5)C(/C(C#N)=C/C(C)(N6CCN(C7COC7)CC6)C)=O)C2=NC=N1
Molecular Formula
C36H40FN9O3
Molecular Weight
665.76
Precautions
P264-P280-P302+P352-P362+P364
References & Citations
[1]KR TW, et al. JPWO2021216696A5. 2024-05-01
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Launched

Chemical Information

Rilzabrutinib

Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune thrombocytopenia (ITP). ITP is an autoimmune disorder characterized by low platelet count. Rilzabrutinib is thought to work by dual mechanisms of action in ITP: It attenuates macrophage (Fcγ receptor)-mediated platelet destruction and reduces the production of pathogenic autoantibodies.

CAS Number1575591-66-0
PubChem CID73388818
IUPAC Name(E)-2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
Molecular FormulaC36H40FN9O3
Molecular Weight665.8
XLogP3.4
Topological Polar Surface Area139
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count11
Rotatable Bond Count8
Heavy Atom Count49
Formal Charge0
Complexity1230
SMILES
CC(C)(/C=C(\C#N)/C(=O)N1CCC[C@H](C1)N2C3=NC=NC(=C3C(=N2)C4=C(C=C(C=C4)OC5=CC=CC=C5)F)N)N6CCN(CC6)C7COC7
InChI
InChI=1S/C36H40FN9O3/c1-36(2,45-15-13-43(14-16-45)26-21-48-22-26)18-24(19-38)35(47)44-12-6-7-25(20-44)46-34-31(33(39)40-23-41-34)32(42-46)29-11-10-28(17-30(29)37)49-27-8-4-3-5-9-27/h3-5,8-11,17-18,23,25-26H,6-7,12-16,20-22H2,1-2H3,(H2,39,40,41)/b24-18+/t25-/m1/s1
InChIKey
LCFFREMLXLZNHE-GBOLQPHISA-N
Chemical Structure
2D Structure
2D structure of Rilzabrutinib
CAS: 1575591-66-0
CID: 73388818
Formula: C36H40FN9O3
MW: 665.8
Interactive 3D Structure
Loading 3D structure...
Computed Properties
PropertyValue
Molecular Weight665.8
XLogP33.4
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count11
Rotatable Bond Count8
Exact Mass665.32381433
Monoisotopic Mass665.32381433
Topological Polar Surface Area139 Ų
Heavy Atom Count49
Formal Charge0
Complexity1230
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count1
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes